# **CLINICAL CASES ALLERGY SCHOOL 2024**

## **GUIDELINES FOR SUBMISSION**



#### General information

For the occasion of the GA<sup>2</sup>LEN Allergy School in Sitges, Barcelona, we are offering you the opportunity to participate in the clinical cases discussion to be held on Saturday, 19 October 2024 as part of a planned range of educational activities.

This is a great opportunity for healthcare professionals to share their experiences, have their case presented in front of key opinion leaders in the field and be acknowledged as active contributors in the GA<sup>2</sup>LEN Allergy School.

All participants with interesting clinical cases are encouraged to submit a case for consideration.

#### Submission rules

Participants may submit up only a case disease area (adults and children), including:

- Allergic airway diseases, including allergic rhinitis and asthma and comorbidities (CRSwNP, N-ERD)
- Drug allergy
- Food allergy
- Mast cells driven diseases
- Urticaria and/or angioedema

The clinical case should be submitted only once: resubmission is not permitted.

A case report must have a short, specific title (containing no abbreviations). A case report summary is limited to 1,950 characters (about 300-350 words). This includes the text plus any graphics, but not the title or authors.

The use of trademarks is prohibited, only International Non-proprietary Names (INN), e.g. generic drug names, are allowed.

Indicate minimum 2, maximum 3 keywords which best correspond to the content of your clinical case. All case reports must be submitted in English with accurate grammar and spelling suitable for publication.

As it is in the intent of Allergy school organization and GA<sup>2</sup>LEN to provide high-quality sessions focused on educational content that is free from commercial influence or bias, all potential conflicts of interest need to be declared.

#### Clinical case format

All abstracts will be submitted in a PDF format based on the following bases.

It is advisable to structure the clinical case in the following sections, following the logical order of evolution:

- Title of the clinical case (abbreviated to coincide with the name of the file). Title should refer to the topic, directly or indirectly, without revealing the diagnosis. The more original, fun, and catchy, the better.
- Introduction/background of one specific case instead of case series.
- Description of clinical history & patient relevant data
- Physical examination
- Tests
- Differential diagnosis
- Description of case challenges/difficulty
- Final diagnosis and therapeutic approach
- Evolution
- Discussion points
- Conclusion
- Bibliography (maximum 7 references, numbered in the text)
- Attached files: maximum 3 tables and/or 3 figures.

## **Authors**

The first author (=presenting author) is responsible for the content and is the contact person for communication purposes and dissemination of information to co-authors.

The first author (=presenting author) should be a person, who personally participated in the described clinical case.

- First author and co-authors need to provide their: full name and affiliation.
- The first author may nominate a co-author to present a clinical case in his/her place, provided that a co-author was a member of the team who was directly involved in the case.
- Ensure that all authors complete the "Conflict of Interest" statement identifying any financial interest in products or processes involved in their activities.

### **Submission date**

• Clinical case submission by email to: clinical-case@allergy-school.com (GA<sup>2</sup>LEN secretariat) will remain open until **30 June 2024** and abstracts might be edited until this time.

#### Selection of clinical cases

All submitted clinical cases will be sent for peer review by a panel of three experts in the field of allergic diseases and urticaria (Scientific Program Committee). Each clinical case will be reviewed and scored to determine which cases are accepted/rejected based on the structure of the abstract (background, clinical case and conclusion).

Clinical case report acceptance/non-acceptance status will be communicated by **Friday, 23 August 2024**. Please ensure that the email provided for the presenting author is accurate as all correspondences will be sent via email, to the presenting author.

The selected 5 abstracts by the Scientific Program Committee, will be presented onsite by the author on **Saturday 19 October 2024** at the **GA**<sup>2</sup>**LEN Allergy School venue in Sitges, Barcelona.** 

The selected clinical case PowerPoint presentations are to be sent to our Audio-Visual team in order to correctly format and align with the Allergy School by no later than **Monday**, **9 September 2024**. Your presentation is allowed to take a maximum of 8 minutes (panoramic format, maximum 10 slides) and will be followed by a short discussion.

Once presented, the Scientific Program Committee and attendees of the meeting will vote the best case based on the following criteria:

- Originality
- Novelty
- Structure of the abstract (background, clinical case and conclusion).
- Duration of the presentation (in compliance with the submission rules)
- Quality of the oral presentation performance

## Notification and registration

Corresponding authors will be notified of acceptance of their clinical case by **Friday**, 23 August 2024.

First author or co-author indicated as presenting author must be attending the meeting or withdraw the Abstract.

#### Awards

There will be two prizes of a full EAACI 2025 Congress registration: one for the best clinical case voted by the Scientific Program Committee and one for the best clinical case voted by the audience.

### Data protection

Participants authorize GA<sup>2</sup>LEN to capture the personal data (name, surname, position or job, image, and voice) during the participation in the clinical cases session.

GA<sup>2</sup>LEN will carry out interviews, photographic reports/audio-visual/sound recordings on its own behalf or through a third party, through capturing images, sound, contributions, interpretations and/or recording by means of video or photography.

Therefore, participants grant GA<sup>2</sup>LEN an irrevocably non-exclusive right to process and use its own image and personal data, in accordance with the provisions of Law 1/1982, of May 5, the Protection of the Right to Honour, Personal and Family Privacy and Own Image.

For this purpose, the participant gives its consent to the process and use its own image and personal data in accordance with the following clauses:

- a) The participant transfers to GA<sup>2</sup>LEN the exploitation rights of the recorded images, for the maximum time allowed by law and for all countries in the world.
- b) The participant gives its consent, without limitation, to the following uses of its own image and name recorded by GA<sup>2</sup>LEN using the technical means currently used and those that may be developed in the future:
  - i) GA<sup>2</sup>LEN will use the recordings to publicize GA<sup>2</sup>LEN's internal activities. The recorded images will be used for promotional activities by GA<sup>2</sup>LEN, in any of the possible formats, including exposure and promotion through the internet and on the different websites of GA<sup>2</sup>LEN.

### **Further Information**

If you have any additional questions or need further information concerning clinical case submission, please contact:

Allergy School GA<sup>2</sup>LEN Abstract Management

E-Mail: clinical-case@allergy-school.com